WaVe Life Sciences (WVE)

Executive Summary

Wave Life Sciences is a clinical-stage RNA therapeutics company leveraging its proprietary PRISM® platform to develop stereopure oligonucleotide treatments for rare genetic disorders and common diseases. The company has a diversified pipeline targeting Duchenne muscular dystrophy (WVE-N531), alpha-1 antitrypsin deficiency (WVE-006), and obesity (WVE-007). Recent data from WVE-006 in AATD showed encouraging safety and biomarker activity, supporting advancement. WVE-007, an RNA-based therapy for obesity, is in Phase 1 with potential to address a large market. Despite earlier setbacks in Huntington's disease (programs terminated), the company's chemistry innovation and focus on validated targets position it for near-term catalysts. With a strong cash position and multiple value-driving events in 2026, Wave represents a high-risk/high-reward opportunity in RNA therapeutics.

Upcoming Catalysts (preview)

• Q4 2026WVE-007 obesity Phase 1 data readout60% success
• Q3 2026WVE-006 AATD Phase 1/2 data from ongoing trial70% success
• Q2 2027WVE-N531 DMD Phase 2 interim efficacy data55% success